PepGen's DM1 Drug Hits 46.5% Splicing Correction in Phase 2, Best Reported to Date
PEPG sits 83% above its 52-week low of $1.31.
Summary
PepGen reported positive topline Phase 2 FREEDOM2-DM1 results at 10 mg/kg, with mean splicing correction of 46.5% at Week 13 versus 6.8% for pooled placebo — the highest level reported in a multiple-dose DM1 study. Five of six treated patients cleared 20% correction and four exceeded 50%. Functional measures moved in the right direction: video hand opening time improved about 52.7% at Week 16 versus 0.2 seconds for placebo, grip strength rose roughly 16.2%, and TUG and 10-meter walk/run also improved. Safety was clean — all adverse events mild or moderate, no serious events, no dose-limiting toxicities, and no discontinuations. This is the key de-risking readout for a micro-cap whose lead program sits under a U.S. partial clinical hold; the 12.5 mg/kg cohort is fully enrolled with data expected in the first half of 2027, and open-label extension data at 5 mg/kg and 10 mg/kg safety are due January 2027. The company also filed its 10-Q today showing $104.8 million in cash and securities, funding operations into 2028.
At the time of this announcement, PEPG was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.5M. The 52-week trading range was $1.31 to $7.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.